Core Insights - Silo Pharma, Inc. has reported positive early data from an ongoing study of its SP-26 ketamine extended-release rods, indicating no serious side effects or discomfort in animal testing [1][2][3] - The SP-26 implant is designed for the treatment of chronic pain and fibromyalgia, with final safety and pharmacokinetic data expected in March 2025 [1][2][3] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as chronic pain, stress-induced psychiatric disorders, and central nervous system diseases [4] - The company's portfolio includes innovative programs like SPC-15 for PTSD and SP-26 for chronic pain and fibromyalgia, with research conducted in collaboration with leading universities and laboratories [4] Product Details - SP-26 is a ketamine-based injectable dissolvable polymer implant aimed at safely regulating dosage and time release for pain relief [3] - If successful in clinical trials, SP-26 may qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval [3]
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia